证券代码：301086 证券简称：鸿富瀚 公告编号：2025-074 深圳市鸿富瀚科技股份有限公司 关于使用暂时闲置超募资金进行现金管理的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 本次事项在公司董事会审议范围之内，无需提交股东会审议。 一、募集资金基本情况 经中国证券监督管理委员会（以下简称"中国证监会"）出具的《关于同意 深圳市鸿富瀚科技股份有限公司首次公开发行股票注册的批复》（证监许可〔2021〕 2743 号）核准，公司本次首次公开发行人民币普通股股票 1,500 万股计划募集 资金总额为 1,449,900,000.00 元，扣除为本次发行支付的发行费用（不含税） 人民币 136,420,351.90 元，实际募集资金净额为人民币 1,313,479,648.10 元。 上述募集资金到位情况经立信会计师事务所（特殊普通合伙）验证，并于 2021 年 10 月 13 日出具信会师报字[2021]第 ZA15656 号验资报告。公司已开设 了募集资金专项账户，对募集资金采取了专户存储，并与专户开户银行、保荐机 构签订了《募集资金 ...

证券代码：301086 证券简称：鸿富瀚 公告编号：2025-073 深圳市鸿富瀚科技股份有限公司 关于2025年前三季度计提资产减值准备的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 单位：人民币元 | 类别 | 项目 | 本期发生额 | | --- | --- | --- | | | | （正号表示损失，负号表示计提冲回） | | 信用减值损失 | 应收票据及应收账款 | 5,982,251.85 | | | 其他应收款 | 6,164.24 | | | 长期应收款 | -31,940.92 | | 资产减值损失 | 存货 | 6,394,938.73 | | | 合同资产 | -185,945.00 | | | 合计 | 12,165,468.90 | 二、本次计提资产减值准备的情况说明 根据《企业会计准则》、公司会计政策的相关规定，本期公司各类资产减值 准备计提情况如下： （一）金融工具减值的测试方法及会计处理方法 深圳市鸿富瀚科技股份有限公司（以下简称"公司"）根据《深圳证券交易 所创业板股票上市规则》《企业会计准则》等相关规定，于2025年 ...

证券代码：301086 证券简称：鸿富瀚 公告编号：2025-072 深圳市鸿富瀚科技股份有限公司 第二届监事会第十六次会议决议公告 一、监事会会议召开情况 深圳市鸿富瀚科技股份有限公司（以下简称"公司"）于 2025 年 10 月 23 日以电子邮件的方式向公司全体监事发出《深圳市鸿富瀚科技股份有限公司第二 届监事会第十六次会议通知》；2025 年 10 月 27 日，公司第二届监事会第十六次 会议（以下简称"本次会议"）以现场结合通讯方式召开。 会议应出席监事 3 名，实际出席监事 3 名，其中廖绍芬女士、张海梅先生以 通讯方式参加会议并表决，本次会议由监事会主席邓佑礼先生主持。董事会秘书 张思明先生列席会议。 本次监事会会议的召集、召开和表决程序符合有关法律、行政法规、部门规 章、规范性文件和《公司章程》的规定。 二、监事会会议审议情况 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 表决结果：同意 3 票；反对 0 票；弃权 0 票。 回避情况：无 1.审议通过《关于<2025 年三季度报告>的议案》 表决结果：同意 3 票；反对 0 票；弃权 0 票 ...

证券代码：301086 证券简称：鸿富瀚 公告编号：2025-071 深圳市鸿富瀚科技股份有限公司 第二届董事会第十七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 深圳市鸿富瀚科技股份有限公司（以下简称"公司"）于 2025 年 10 月 23 日以电子邮件的方式向公司全体董事发出《深圳市鸿富瀚科技股份有限公司第二 届董事会第十七次会议通知》；2025 年 10 月 27 日，公司第二届董事会第十七 次会议（以下简称"本次会议"）以现场结合通讯方式在深圳市龙岗区宝龙街道 宝龙社区拓新路 11 号鸿富瀚科技大楼 1 栋公司会议室召开。 本次会议应参与表决的董事 7 人，实际参与表决的董事 7 人（其中：以通讯 表决方式出席会议的董事 4 人），董事长张定武先生、独立董事黄延禄先生、刘 善敏先生及张振煌先生以通讯方式参加会议并表决，本次会议由副董事长张定概 先生主持。全体监事、全体高级管理人员列席会议。 本次董事会会议的召集、召开和表决程序符合有关法律、行政法规、部门规 章、规范性文件和《公司章程》的规定。 二、董事会会议 ...

鸿富瀚公告，第三季度营收为2.95亿元，同比增长6.11%；净利润为5892.37万元，同比下降5.36%。前 三季度营收为6.5亿元，同比增长7.87%；净利润为8165.56万元，同比下降25.79%。 ...

Core Viewpoint - The company announced a total of 12.1655 million yuan in credit impairment losses and asset impairment losses for the first three quarters of 2025, which will reduce the total profit for the consolidated financial statements from January to September 2025 by the same amount [1] Summary by Categories - **Credit Impairment Losses** - The company recognized 5.9823 million yuan in impairment losses for notes receivable and accounts receivable [1] - **Other Receivables** - An impairment loss of 0.616424 million yuan was recorded for other receivables [1] - **Long-term Receivables** - The company reversed 3.194092 million yuan in long-term receivables [1] - **Inventory** - An impairment loss of 0.63949 million yuan was recognized for inventory [1] - **Contract Assets** - The company reversed 0.1859 million yuan in contract assets [1]

Financial Performance - The company's revenue for Q3 2025 was CNY 294,509,269.40, representing a year-over-year increase of 6.11%[5] - The net profit attributable to shareholders decreased by 5.36% to CNY 58,923,652.48 for the quarter, and year-to-date net profit fell by 25.79% to CNY 81,655,566.59[5] - The basic earnings per share for Q3 2025 was CNY 0.66, down 4.35% compared to the same period last year[5] - The total revenue for the current period reached RMB 649.92 million, representing an increase of 7.79% compared to RMB 602.53 million in the previous period[28] - The net profit for the current period was RMB 77.03 million, a decrease of 30.05% from RMB 110.22 million in the previous period[29] - Basic and diluted earnings per share were both reported at ¥0.91, compared to ¥1.22 in the previous period, indicating a decline of about 25%[30] - The company's total comprehensive income attributable to the parent company was ¥81,655,566.59, down from ¥110,026,654.44, reflecting a decrease of approximately 26%[30] Assets and Liabilities - Total assets increased by 12.25% to CNY 2,997,187,833.58 compared to the end of the previous year[5] - As of September 30, 2025, the total assets amounted to RMB 2.997 billion, an increase from RMB 2.670 billion at the beginning of the period, reflecting a growth of approximately 12.24%[24][26] - The company's total liabilities increased significantly, with current liabilities rising by 171.76% to CNY 6,755,256.94, attributed to the increase in commercial acceptance bills[10] - The total current liabilities increased to RMB 898.03 million from RMB 592.90 million, an increase of 51.49%[26] Cash Flow - Cash flow from operating activities for the year-to-date period was CNY 122,805,432.35, an increase of 52.97%[5] - Cash received from operating activities increased by 210.14% to ¥65,437,026.02, primarily due to the recovery of restricted funds[13] - Cash paid for operating activities rose by 116.73% to ¥157,507,921.99, mainly attributed to an increase in restricted funds[13] - The company's net cash flow from operating activities increased to ¥122,805,432.35, up from ¥80,279,707.77 in the previous period, representing a growth of approximately 53%[31] - Total cash inflow from operating activities reached ¥907,364,536.04, compared to ¥676,489,903.32 in the prior year, indicating a year-over-year increase of about 34%[32] - Cash flow from financing activities generated a net inflow of ¥158,016,868.84, significantly higher than the previous year's net inflow of ¥35,591,677.75, marking an increase of over 344%[33] Investments and Shareholder Actions - The company plans to invest approximately RMB 1.41 billion in establishing a joint venture in the Democratic Republic of the Congo to build a photovoltaic energy storage project, with the company's investment not exceeding RMB 1.128 billion[22] - The company repurchased a total of 339,500 shares, accounting for 0.38% of the total share capital, with a total transaction amount of ¥20,009,800 (excluding transaction fees)[19][20] - The maximum repurchase price was adjusted to ¥61.20 per share after the 2024 annual equity distribution[19] - Major shareholder Zhang Dingwu holds 59.75% of the shares, totaling 53,777,250 shares[16] - The company plans to reduce the holdings of Vice Chairman Zhang Dingkai by up to 776,250 shares, representing 0.8658% of the total share capital[21] Accounts Receivable and Inventory - The accounts receivable rose by 32.45% to CNY 482,677,597.02, indicating an increase in outstanding payments[10] - The accounts receivable rose to RMB 482.68 million, up from RMB 364.42 million, marking an increase of 32.41%[24] - The company's inventory increased to RMB 143.77 million from RMB 119.68 million, reflecting a growth of 19.99%[24] Financial Expenses and Impairments - The company recorded a 771.82% increase in credit impairment losses, amounting to CNY -5,956,475.17, reflecting higher provisions for bad debts[12] - The company’s financial expenses surged by 133.56% to CNY 3,376,021.40, mainly due to increased interest expenses[12]

Group 1 - Xuedilong plans to invest no more than 400 million yuan to build an innovation industrial base in Changping District, Beijing, focusing on chromatography and mass spectrometry production lines [1] - The project aims to enhance research and production capabilities in carbon monitoring and measurement systems [1] Group 2 - Zejing Pharmaceutical's tri-specific antibody drug ZGGS34 has received clinical trial approval from the National Medical Products Administration for treating MUC17 positive advanced solid tumors [2] - The drug shows strong anti-tumor activity and good safety in preclinical studies [2] Group 3 - Aosaikang's new cMET inhibitor ASK202 will present clinical research data at the 2025 ESMO annual meeting, showing an objective response rate of 68.8% and a disease control rate of 93.8% in advanced non-small cell lung cancer patients [2][3] Group 4 - China Life expects a net profit of 156.785 billion to 177.689 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 50% to 70% [4] Group 5 - Silan Microelectronics plans to jointly invest 5.1 billion yuan to build a 12-inch high-end analog chip production line, with a total project investment of 20 billion yuan [5][6] Group 6 - New City intends to use 156.65 million yuan of remaining fundraising to invest in a "Building Green Energy and Zero Carbon Park" project, with a total investment of 257 million yuan [8] Group 7 - Yidao Information plans to acquire control of Guangzhou Langguo Electronic Technology and Shenzhen Chengwei Information through a combination of share issuance and cash payment [9] Group 8 - Xiling Information's controlling shareholder has received a notice of lifting restrictions, allowing normal business operations to resume [10] Group 9 - Dongpeng Holdings' first batch of rock slab products has passed the highest level 5A quality inspection, becoming one of the first companies to meet the new national standard [11] Group 10 - Aonlikang's levofloxacin tablets have received approval from the National Medical Products Administration, classified as a chemical drug of category 4 [15] Group 11 - Haizheng Pharmaceutical's Taizhou factory has had its GMP non-compliance declaration revoked by the EU, confirming compliance with EU GMP requirements [17][18] Group 12 - Hongfuhan's shareholder plans to reduce its stake by up to 1.5% through various trading methods due to asset integration and funding needs [19] Group 13 - Purang Co. plans to establish a wholly-owned subsidiary in Hong Kong to enhance its international competitiveness and service levels [20] Group 14 - Tianhe Magnetic Materials' subsidiary has signed an investment agreement for a project worth 850 million yuan focused on high-performance rare earth permanent magnets [22] Group 15 - Xiangfenghua reported a 64.64% year-on-year decline in net profit for the first three quarters, despite an 8.16% increase in revenue [23] Group 16 - Darui Electronics reported a 26.84% year-on-year increase in net profit for the first three quarters, with total revenue growing by 28.59% [24] Group 17 - Xiangsheng Medical reported a 4.56% year-on-year decline in net profit for the first three quarters, despite a 41.95% increase in net profit for the third quarter [25]

Core Viewpoint - Hongfuhuan announced that its second-largest shareholder, Hengmei International, plans to reduce its stake by 1.50% from November 10, 2025, to February 9, 2026, due to asset integration and funding needs [1][2]. Shareholder Information - Hengmei International holds 5.4 million shares, representing 6.02% of the total shares before the planned reduction [2]. - The company’s vice chairman and general manager, Zhang Dingge, also announced a plan to reduce his stake by 0.87% from October 20, 2025, to January 19, 2026 [2]. Financial Performance - In the first half of 2025, the company reported revenue of CNY 355.41 million, a year-on-year increase of 9.37%, but net profit fell by 52.41% to CNY 22.73 million [3][5]. - The gross margin decreased by 6.6 percentage points to 29.39%, and the net margin shrank by 9.09 percentage points [3][5]. - The company’s net cash flow from operating activities decreased by 46.84% compared to the previous year [5]. Cost and Expense Analysis - The company’s period expenses increased by CNY 16.11 million year-on-year, with a period expense ratio of 22.92%, up 2.81 percentage points [6]. - Sales expenses rose by 20.42%, management expenses by 26.66%, R&D expenses by 9.96%, and financial expenses surged by 247.56% [6]. Market Performance - As of the report date, Hongfuhuan's stock price was CNY 72.90 per share, with a total market capitalization of approximately CNY 6.561 billion, reflecting a year-to-date increase of over 40% [6][7].

转自：中国证券报·中证网 公告显示，恒美国际持有公司股份540万股，占公司总股本比例为6.02%。此次减持的原因是恒美国际 股东资产整合、资金周转及自身业务需要，计划减持的股份来源为公司首次公开发行股票并上市前持有 的股份（含该等股份首次公开发行后因利润分配或者资本公积金转增股本而相应增加的股份）。 公告披露，此次恒美国际减持拟通过集中竞价和大宗交易方式进行，合计减持股份数量不超过134.49万 股（占公司总股本1.50%）。其中，在任意连续90个自然日内，以集中竞价交易方式减持股份的总数不 超过89.66万股，即不超过公司总股本的1.00%；以大宗交易方式减持股份的总数不超过44.83万股，即 不超过公司总股本的0.50%。 中证报中证网讯（王珞）10月19日晚，鸿富瀚发布公告称，公司股东恒美国际有限公司（以下简称"恒 美国际"）计划在2025年11月10日至2026年2月9日减持公司股份不超过134.49万股，即不超过公司总股 本的1.50%。 ...